Rainbow Children's Medicare Limited conducted an earnings conference call on November 2, 2026, to discuss its unaudited financial results for Q2 FY27 (quarter ended September 30, 2026). The call was hosted by IIFL Capital with management participants including Dr. Ramesh Kancharla (Chairman and MD), Mr. Abrarali Dalal (Group CEO), Mr. Sudarshan Patodia (Group CFO), and Mr. Saurabh Bhandari (Head Investor Relations).

Financial Performance

  • Revenue: Q2 FY27 revenue grew 23.2% year-on-year to ₹548 crores. H1 FY27 revenue stood at ₹1,018 crores, reflecting 27.6% growth compared to H1 previous year.
  • EBITDA: Q2 FY27 EBITDA amounted to ₹170 crores, marking 14.2% growth year-on-year. H1 FY27 EBITDA was ₹304.6 crores, showing 20.6% growth.
  • EBITDA Margin: 31% for Q2 FY27 and 29.9% for H1 FY27.
  • PAT: Profit after tax for Q2 stood at ₹83.9 crores (10.9% growth year-on-year). H1 PAT was ₹146.4 crores (13.1% growth).
  • Operational Metrics: Patient consultations grew 19% year-on-year, deliveries grew 20%, and inpatient discharges registered 15% growth in Q2. For H1, outpatient consultations, deliveries, and inpatient discharges grew by 21%, 22%, and 21% respectively.
  • Payer Mix: Q2 FY27 - 63.3% cash patients, 36.7% insurance. H1 FY27 - 64.2% cash, 35.8% insurance.
  • Balance Sheet: Cash equivalents, fixed deposits, and mutual fund investments aggregated to ₹542.8 crores as of September 30, 2026.
  • Capex: Company incurred capital expenditure of ₹81.9 crores during the quarter toward hospital network development and enhancement.

Expansion and Capacity Update

  • Commenced operations at newly acquired 70-bed hospital in Nellore and 50-bed brand-new hospital in Guntur.
  • Government of Andhra Pradesh allotted 2 acres of land in Amaravati for pediatric specialty hospital (150 beds planned in 2 phases).
  • Current pipeline: 1,050 beds at various construction stages.
  • Project Timeline Details:
  • Indore: Clinical operations expected in Q3 FY27; 120-bed greenfield project groundbreaking expected on Diwali
  • Mumbai (Malad): 100-bed brownfield hospital in active construction, targeting Q1 FY28 operations
  • Coimbatore: 130-bed greenfield hospital expected for internal works April 2027, operations in Q3 FY28
  • Gurgaon: Sector 56 (125 beds) expected operations Q3 FY28; Sector 44 (325-bed hub) expected Q1 FY29
  • Bangalore: 100-bed hospital in Seegehalli and Pune: 150-bed greenfield hospital likely ready second half FY29

Operational Initiatives

  • Implemented "One Rainbow Model" clinical governance framework for standardized care protocols
  • New Hospital Information System (HIS) implementation live in Hyderabad hub hospital, with full rollout expected in 4 months
  • Complex liver transplant surgery performed on 6-week-old baby (2.9 kg) highlighting surgical capabilities
  • Marketing expense at little over 2% of revenue, focusing on digital channels, community engagement, and loyalty program (Shield card)
  • New website and patient app planned for launch in coming months

Management Guidance and Commentary

  • Margin Outlook: Expect to maintain pre-Ind AS EBITDA margins around 25-26% despite expansion; new hospital impact estimated at 0.5% margin compression
  • Expansion Strategy: Focus on North Indian markets (Delhi NCR, Lucknow, Jaipur, Bhubaneswar, Chandigarh); target EBITDA breakeven within 2 years for new hospitals
  • Growth Target: Stated expectation of high-teens growth, optimistic about potential for higher topline growth
  • Payer Mix: Expect blended mix of approximately 60:40 (cash:insurance); government business accounts for less than 1%
  • ARPOB Growth: Normal expectation of 7-8%; current 15% growth driven by case mix, obstetrics growth, fertility contribution, and reduced ALOS
  • Occupancy Target: Maximum 60% for mature hospitals; currently at 54% despite seasonal softness
  • IVF Business: Contributes 5% of revenue; expected to grow proportionally with obstetrics OPD expansion
  • Pharmacy Impact: Pharmacy costs at 14% of net revenue; potential drug price cap impact estimated at less than 0.5% of revenue